Author Archives: Marta Figueiredo PhD

Xentria Readies First Trial of XTMAB-16 for Sarcoidosis

The U.S. Food and Drug Administration (FDA) has approved beginning clinical trials testing XTMAB-16, Xentria’s investigational TNF-alpha inhibitor for the treatment of sarcoidosis. The first, a Phase 1 trial evaluating the therapy in healthy volunteers, is expected to start in July at the Parexel Baltimore Early Phase…

Sarcoidosis Advocate Appointed Patient Advisor at aTyr

aTyr Pharma, which is developing a candidate therapy for pulmonary sarcoidosis called ATYR1923, has appointed Andrea Wilson — a sarcoidosis patient and advocate who co-founded the Foundation for Sarcoidosis Research (FSR) — as a patient advisor. “We are pleased during Sarcoidosis Awareness Month to welcome Andrea, a…